Context: Caelus Lifesciences IP B.V., a Dutch company that develops microbiome ingredients from human gut bacteria, co-owns EP2753187 (“Method for preventing and/or treating insulin resistance”) on using certain gut bacteria against insulin resistance with Amsterdam UMC. Pendulum Therapeutics Inc. of San Francisco sells the probiotic products Glucose Control and Metabolic Daily, which iHerb Netherlands B.V. also offers online.
To Read The Full Story
Continue reading your article with a Membership
Court and counsel
Court: UPC Hague LD, Judge Edger Brinkman
Counsel for Caelus: Brinkhof’s D.F. de Lange, B.B. van der Wansem, and R. Rijpkema, together with Plasseraud’s J. Renes.
Counsel for Pendulum and iHerb: Winston Taylor’s Sebastien M.M. Versaevel and Prof. Dr. Wim Maas.